Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient population
CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic and memory T cells associated with subsequent prolonged survival, and a beneficial effect on both injected and uninjected tumors
Recent CADL News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2025 08:15:31 PM
- Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 • GlobeNewswire Inc. • 04/23/2025 08:05:00 PM
- Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients • GlobeNewswire Inc. • 04/01/2025 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2025 01:57:07 AM
- Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment • GlobeNewswire Inc. • 03/26/2025 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2025 08:36:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2025 08:35:42 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/20/2025 08:35:16 PM
- Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 • GlobeNewswire Inc. • 03/20/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2025 08:12:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2025 08:06:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2025 08:29:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2025 08:29:39 PM
- Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board • GlobeNewswire Inc. • 03/18/2025 12:00:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2025 08:29:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2025 08:29:31 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/13/2025 08:45:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2025 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2025 08:15:08 PM
- Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/13/2025 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2025 01:15:09 PM
- Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 02/25/2025 01:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 09:30:06 PM
FEATURED Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM